Simms S G, Rhodes V A, Madsen R W
Ellis Fischel Detection and Information Program, University of Missouri Hospitals and Clinics, Columbia.
Nurs Res. 1993 Jul-Aug;42(4):234-9.
This randomized, double-blind crossover study was undertaken to compare the antiemetic effectiveness of intravenous prochlorperazine (Compazine) and lorazepam (Ativan) in the management of postchemotherapy symptoms during two initial cycles of therapy. Each patient received at least one treatment as an outpatient. Data from the 24 patients receiving noncisplatin therapy who completed the crossover study were evaluated for antiemetic efficacy and total posttherapy symptom experience. Although results indicated no statistically significant difference between regimens in the control of posttherapy nausea and vomiting, these side effects were completely controlled in 26 of the 48 study treatment cycles. Lorazepam significantly reduced total posttherapy symptom experience by decreasing patients' experience of fatigue and pain. Findings support the value of lorazepam in antiemetic regimens and point to the need for further examination of antiemetic combinations.
这项随机、双盲交叉研究旨在比较静脉注射丙氯拉嗪（康帕嗪）和劳拉西泮（阿替凡）在两个初始治疗周期中对化疗后症状的止吐效果。每位患者至少作为门诊患者接受一次治疗。对完成交叉研究的24例接受非顺铂治疗的患者的数据进行了止吐疗效和治疗后总症状体验评估。虽然结果表明两种治疗方案在控制治疗后恶心和呕吐方面无统计学显著差异，但在48个研究治疗周期中的26个周期中，这些副作用得到了完全控制。劳拉西泮通过减少患者的疲劳和疼痛体验，显著降低了治疗后总症状体验。研究结果支持劳拉西泮在止吐方案中的价值，并指出需要进一步研究止吐联合用药。
